Germany - Open framework agreement on drug discounts pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, with the option to join at any time, so-called approval model 2022-10

Description

The purpose of this notice is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) Sentence 1 of the German Social Code, Book Five (SGB V) (discount agreements). Pursuant to Section 130a (8) Sentence 1 of the German Social Code, Book V, the invitation to participate is directed only to pharmaceutical companies or associations of employees of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join rebate contracts with conditions that are fixed and non-negotiable for all participants, including the amount of the rebate. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (AMG) may become contract partners. The conclusion of the contract or an accession takes place by the required completed self-declarations or proofs as well as the contract(s) being either
a) signed by hand (written form according to § 126 BGB) by mail or
b) with a qualified electronic signature (§ 126a BGB) by sending an e-mail to openhouse.rabattvertrag2022-10@kbs.de to the CAB.
The earliest start of the contract is 01.10.2022, provided that the contract and the required declarations or evidence have been received by the CAB by 05.09.2022 at the latest. The start of the contract is therefore the 1st of the month following the month of receipt of the contract and the required declarations or evidence by the CAB, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts end automatically, without the need for termination, as soon as contract partners for the active ingredient(s) or active ingredient combination(s) have been identified by means of a formal award procedure. The deadline for receipt of accessions is 05.08.2024. In any case, the contracts end on 30.09.2024.
The active ingredients/active ingredient combinations can be found in the attachment "Advertisement text".
The link to the contract documents must be requested by e-mail (openhouse.rabattvertrag2022-10@kbs.de). The documents will be made available on the homepage of the CAB.

Opportunity closing date

05 August 2024

Value of contract

to be confirmed